logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10155044 B1

PDFFull Text
Date of Patent:
Dec. 18, 2018

Filed:

Feb. 07, 2017

Methods and compositions for deterring abuse

Applicant:

Acura Pharmaceuticals, Inc., Palatine, IL (US);

Inventors:

Ronald L. Leech, Plymouth, IN (US);

Rachelle L. Hall Yung, Argos, IN (US);

Albert W. Brzeczko, Roswell, GA (US);

Assignee:

Acura Pharmaceuticals, Inc., Palatine, IL (US);

Attorney:

Morgan, Lewis & Bockius LLP

Primary Examiner:

Kathrien A Cruz

Int. Cl.
CPC ...
A61K 31/5517 (2006.01); A61K 31/137 (2006.01); A61K 31/4458 (2006.01); A61K 31/485 (2006.01); A61P 25/30 (2006.01); A61P 25/04 (2006.01); A61K 47/38 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/32 (2006.01);
U.S. Cl.
CPC ...
A61K 47/38 (2013.01); A61K 9/1635 (2013.01); A61K 9/1652 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2072 (2013.01); A61K 31/137 (2013.01); A61K 31/4458 (2013.01); A61K 31/485 (2013.01); A61K 31/5517 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/32 (2013.01);
Abstract

Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.

Find Patent Forward Citations

Loading…